The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.

Say goodbye to the classic ClinicalTrials.gov!

The classic ClinicalTrials.gov website will be retired on June 25, 2024. Please use the modernized ClinicalTrials.gov. For more information, see ClinicalTrials.gov Modernization.

Key Record Dates

ClinicalTrials.gov Identifier:	NCT03037385
Brief Title:	Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors (ARROW)

First Submitted :	January 20, 2017
First Submitted that Met QC Criteria :	January 27, 2017
First Posted :	January 31, 2017 (Estimate)

Last Update Submitted that Met QC Criteria :	April 10, 2024
Last Update Posted :	April 11, 2024

To Top